"Time","Event","Arm","Expression","Figure","Trial","Outcome","Units","Disease"
"0.427","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"0.56","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"0.726","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"1.3","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"1.39","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"1.89","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"2.38","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"2.41","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"2.7","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"2.74","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"2.85","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"2.9","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"2.99","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"3","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"3.57","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"3.8","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"3.83","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"4.08","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"4.12","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"4.16","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"5.82","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.02","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.06","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.43","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.57","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.99","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.47","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.52","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.59","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.72","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"8.66","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"8.81","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"8.81","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.09","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.76","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.86","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.86","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.2","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.7","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.8","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.9","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.5","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.3","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.6","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"14","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"14.4","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"15","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"15.2","1","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"1.5","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"4.49","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.22","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.425","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.65","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.85","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.07","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.29","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.505","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.705","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.925","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"8.14","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"8.36","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"8.58","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"8.75","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.12","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.21","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.32","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.43","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.52","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.635","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.725","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.82","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.93","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.05","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.15","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.25","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.35","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.45","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.55","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.65","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.75","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.85","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.95","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.05","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.15","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.25","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.35","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.45","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.55","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.65","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.75","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.85","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.15","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.35","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.45","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.65","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.85","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.95","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.15","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.35","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.45","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.65","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.85","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.95","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"14.15","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"14.35","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"14.45","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"14.65","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"14.85","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"15.25","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"15.45","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"15.65","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"15.95","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"16.15","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"16.35","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"16.65","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"16.85","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"17.05","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"17.35","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"17.55","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"17.75","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"18.25","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"18.45","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"18.75","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"18.95","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"19.25","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"19.45","0","pembrolizumab-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"0.501","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"0.696","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"1.23","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"2","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"2.05","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"2.17","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"2.35","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"2.74","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"2.94","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"3.23","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"3.69","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"3.92","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"3.96","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"4.28","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"4.49","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"4.7","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"4.9","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"5.39","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"5.4","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"5.94","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.83","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.91","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"7.26","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"7.71","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.16","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.32","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.32","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.42","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.44","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.74","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.9","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.4","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.1","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.3","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.4","1","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.215","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.395","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.565","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.775","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.95","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"7.125","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"7.335","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"7.515","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"7.665","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"7.895","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.075","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.25","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.455","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.635","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.815","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.105","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.195","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.285","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.425","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.505","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.59","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.705","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.785","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.905","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.99","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.05","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.15","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.25","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.35","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.45","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.55","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.65","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.8","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.8","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.95","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.05","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.15","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.25","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.35","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.45","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.55","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.65","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.75","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.85","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.15","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.25","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.35","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.45","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.55","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.65","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.75","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.85","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.95","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.05","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.15","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.25","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.35","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.45","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.65","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.75","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.85","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.95","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.05","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.15","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.25","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.35","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.45","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.55","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.65","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.75","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.85","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"15.15","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"15.35","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"15.55","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"15.75","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"15.85","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"16.05","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"16.25","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"16.45","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"16.55","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"16.75","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"16.95","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"17.15","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"17.25","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"17.45","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"17.65","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"17.85","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"18.35","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"18.75","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"19.15","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"19.55","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"19.95","0","pembrolizumab-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"0.16","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"0.266","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"0.268","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"0.525","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"0.655","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"1.12","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"1.55","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"1.96","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"2.39","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"3.91","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4.01","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4.27","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4.64","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4.93","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"5.22","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"5.72","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"5.84","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"6.21","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"6.67","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.59","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.86","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.05","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.07","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.1","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.19","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.95","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.47","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.58","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.71","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.6","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.1","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.5","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13","1","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"1.485","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"6.31","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"6.615","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"6.9","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.21","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.515","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.81","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.105","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.41","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.705","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.09","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.195","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.26","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.35","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.43","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.545","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.61","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.685","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.775","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.87","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.94","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.05","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.15","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.25","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.25","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.35","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.45","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.55","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.65","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.75","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.85","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.85","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.95","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.05","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.15","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.25","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.35","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.45","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.45","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.55","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.65","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.75","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.85","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.95","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.05","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.15","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.25","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.35","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.45","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.55","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.65","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.75","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.85","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.95","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.05","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.15","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.25","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.35","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.45","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.55","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.65","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.75","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.85","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.95","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.05","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.15","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.25","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.35","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.45","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.55","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.65","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.75","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.85","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"15.15","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"15.25","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"15.45","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"15.55","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"15.75","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"15.85","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"16.05","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"16.15","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"16.35","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"16.45","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"16.65","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"16.75","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"16.95","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"17.05","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"17.25","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"17.35","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"17.55","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"17.65","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"17.85","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"18.15","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"18.35","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"18.55","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"18.75","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"18.95","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"19.15","0","pembrolizumab-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"0.38","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"0.433","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"1.2","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"1.61","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"1.61","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"2.98","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"3.08","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"3.19","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"3.25","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"3.29","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"3.5","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4.03","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4.2","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4.3","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4.5","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4.76","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"4.96","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"5.12","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"5.44","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"6.16","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"6.64","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"6.7","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"6.83","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.14","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.38","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.52","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.76","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.09","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.42","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.06","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.09","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.23","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.75","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"15.1","1","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"6.51","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.015","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"7.48","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.045","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"8.5","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.26","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.5","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"9.76","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.05","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.25","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.55","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"10.75","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.05","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.25","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.55","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"11.75","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.45","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"12.85","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.25","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"13.75","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.15","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"14.55","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"15.35","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"15.65","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"15.95","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"16.35","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"16.65","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"16.95","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"17.35","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"17.65","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"18.25","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"18.45","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"18.75","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"18.95","0","placebo-combo",">=50% pd-l1","2C","Keynote 189","OS","Month","NSCLC"
"0.716","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"1.07","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"1.1","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"1.13","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"1.27","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"1.82","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"2.28","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"2.31","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"2.83","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"3.47","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"3.67","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"3.72","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"4.28","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"4.36","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"4.77","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"4.82","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"4.88","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"5.27","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.41","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.45","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.51","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.54","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"6.94","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.24","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.58","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.59","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.64","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"8.16","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.69","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.1","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.2","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.5","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.5","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.6","1","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"7.01","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"8.01","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.28","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.62","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"9.81","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.05","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.35","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.65","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"10.95","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.15","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.45","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"11.75","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.25","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.55","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"12.85","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.35","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.65","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"13.95","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"14.15","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"14.45","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"14.75","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"15.45","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"15.95","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"16.5","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"16.95","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"17.45","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"18.65","0","placebo-combo","<1% pd-l1","2A","Keynote 189","OS","Month","NSCLC"
"0.601","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"0.768","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"2.26","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"2.78","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"4.07","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"4.61","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"4.69","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"4.69","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"5.17","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"5.33","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"5.58","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.18","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.2","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.54","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.61","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.67","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"7.33","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"7.99","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.13","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.66","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.73","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.73","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.92","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.3","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.7","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.8","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.4","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13","1","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"6.775","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"7.515","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"8.255","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.255","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.515","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"9.755","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.05","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.25","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.55","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"10.75","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.05","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.25","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.55","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"11.75","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.25","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.45","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.75","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"12.95","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.25","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.45","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.75","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"13.95","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.25","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.45","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"14.75","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"15.75","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"16.45","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"17.25","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"18.55","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
"19.15","0","placebo-combo",">=1% pd-l1 <50%","2B","Keynote 189","OS","Month","NSCLC"
